Mitochondrial encephalomyopathies.
Mitochondrial diseases are uniquely interesting from a genetic point of view because mitochondria contain their own DNA (mtDNA) and are capable of synthesizing a small but vital set of proteins, all of which are components of respiratory chain complexes. Numerous mutations in mtDNA have been described in the past 5 years, and, it is, therefore, important for the clinician to keep in mind both some characteristic clinical presentations and, more importantly, some basic principles of "mitochondrial genetics," including heteroplasmy, the threshold effect, mitotic segregation, and maternal inheritance. The vast majority of mitochondrial proteins are encoded by nuclear DNA (nDNA) and have to be imported from the cytoplasm into mitochondria through a complex translocation machinery, which is also under the control of the nuclear genome. In addition, nDNA encodes several factors that control mtDNA replication, transcription, and translocation. Mitochondrial diseases due to mutations in nDNA are transmitted as mendelian traits and fall into three categories: (1) alterations of mitochondrial proteins; (2) alterations of mitochondrial protein importation; and (3) alterations of intergenomic communication. The first group of disorders can be further classified on the basis of the biochemical area affected, including defects of transport, defects of substrate utilization, defects of the Krebs cycle, defects of oxidation/phosphorylation coupling, and defects of the respiratory chain. The second group includes only few well-documented disorders but will certainly expand in the near future. The third group includes two conditions, an autosomal dominant form of progressive external ophthalmoplegia associated with multiple mtDNA deletions, and a quantitative defect of mtDNA (mtDNA depletion) causing severe infantile myopathy or hepatopathy.
DiMauro
S
S
H. Houston Merritt Clinical Research Center for Muscular Dystrophy and Related Diseases, College of Physicians and Surgeons, Columbia University, New York, NY.
Moraes
C T
CT
D002872:Chromosome Deletion; D030401:Cytochrome-c Oxidase Deficiency; D004247:DNA / Q000235:genetics; D004261:DNA Replication; D004272:DNA, Mitochondrial / Q000235:genetics*; D042963:Electron Transport Complex II; D003576:Electron Transport Complex IV / Q000235:genetics; D006801:Humans; D017241:MELAS Syndrome / Q000235:genetics; D017243:MERRF Syndrome / Q000235:genetics; D017237:Mitochondrial Encephalomyopathies / Q000175:diagnosis / Q000235:genetics*; D008938:Mitosis; D009097:Multienzyme Complexes / Q000172:deficiency / Q000235:genetics; D009154:Mutation; D016660:NAD(P)H Dehydrogenase (Quinone) / Q000172:deficiency / Q000235:genetics; D015418:Optic Atrophies, Hereditary / Q000235:genetics; D010088:Oxidoreductases / Q000172:deficiency / Q000235:genetics; D017354:Point Mutation; D013385:Succinate Dehydrogenase / Q000172:deficiency / Q000235:genetics
D004272:DNA, Mitochondrial; D009097:Multienzyme Complexes; D004247:DNA; D010088:Oxidoreductases; D042963:Electron Transport Complex II; D013385:Succinate Dehydrogenase; D016660:NAD(P)H Dehydrogenase (Quinone); D003576:Electron Transport Complex IV